Scienture Holdings, Inc.

Scienture Holdings reported second-quarter revenue of $0.34 million, a sequential increase of approximately 510 percent. Non-GAAP net loss per share was $0.07. Net loss narrowed 58 percent year-over-year to $2.82 million from $6.72 million. Gross profit was $0.34 million with a gross margin of approximately 97.7 percent. Cash, cash equivalents, and restricted cash totaled $11.20 million as of June 30, 2026. First-half 2026 revenue rose to $0.40 million from $0.01 million in the first half of 2025.

Scienture Holdings has completed manufacturing of commercial launch inventory for REZENOPY Nasal Spray 10 mg and will begin shipments to US pharmaceutical wholesalers in July, with broad availability expected in August. REZENOPY is the highest-dose FDA-approved naloxone nasal spray in the United States, delivering 10 mg in a single-use device for emergency treatment of known or suspected opioid overdose. IQVIA data show the US naloxone market totals about $144 million annually across 9.8 million units, and the company noted expanded payer access with potential coverage reaching more than 100 million lives. The stock rose to $0.39 in overnight trading, up 18.59%, after closing Thursday at $0.33.